Healthcare Reform: Employers and Narrow Networks Could Drive Cost-Effective Patient Outcomes
Employers and Medicare trustees could come together and change the healthcare industry, leading to healthcare reform, according to Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company.
Luke Hansen, M.D., M.H.S., chief medical officer of Arcadia, a healthcare data analytics company, said that healthcare reform won’t be easy, specifically when it comes to stronger incentives for value-based care.
Luke Hansen, M.D., M.H.S.
“There are many people in their 40s, 50s, 60s—commercially insured with chronic disease—and their employers are holding the bag, and their employers have a fiduciary responsibility to manage those lives optimally,” Hansen said. “I don't think that we've totally taken advantage of that opportunity. If a large enough cohort of employers came together, they could move the industry, and they could by delegating through narrow networks to high performance provider organizations.”
He continued by explaining that change requires risk.
“You have to be willing to take some risks with constituencies,” Hansen said during a video interview with Managed Healthcare Executive. “I think it starts with attribution and responsibility for cost, which isn’t present in the majority of people administering healthcare.”
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More
